Sacral nerve stimulation

Asia-Pacific Neurostimulation Devices Markets, Competition, Forecast & Opportunities, 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 25, 2023
Neurology, Health, Medical Devices, SCSI Peripheral Device Type, Forecast, Neurology India, Headache, Laboratory, Alzheimer's disease, Sacral nerve stimulation, Vagus nerve stimulation, Abbott Laboratories, Country, Boston Scientific, World Health Organization, Spinal cord stimulator, Competition, Incidence, Asthma, Tic disorder, Depression, Cerebral palsy, Research, Interstitial cystitis, Application, WHO, DSM-IV codes, Stroke, Migraine, Neuropathic pain, Growth, Neurostimulation, Partnership, Parkinson's disease, Tetraplegia, Epilepsy, Medtronic, Medical device, Pharmaceutical industry, Semiconductor, Video game, Airline, Online shopping

Asia-Pacific neurostimulation devices market is expected to grow at a significant rate during the forecast period.

Key Points: 
  • Asia-Pacific neurostimulation devices market is expected to grow at a significant rate during the forecast period.
  • To estimate and forecast the market size of Asia-Pacific neurostimulation devices market from 2022 to 2028 and growth rate until 2028.
  • To classify and forecast Asia-Pacific neurostimulation devices market based on device type, application, company and country-wise distribution.
  • To identify key sustainable strategies adopted by market players in Asia-Pacific neurostimulation devices market.

Axonics® Files PMA Supplement with the FDA for Non-Rechargeable Implantable Sacral Neurostimulator

Retrieved on: 
Thursday, June 24, 2021
Biotechnology, FDA, Medical devices, Other Health, Health, Branches of biology, Medical specialties, Clinical medicine, Neurotechnology, Incontinence, Urinary incontinence, Sacral nerve stimulation, Neuromodulation, Stress incontinence, Fecal incontinence

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has filed a premarket approval (PMA) supplement with the FDA for its newly developed, long-lived, non-rechargeable sacral neuromodulation (SNM) implantable neurostimulator (INS).

Key Points: 
  • Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has filed a premarket approval (PMA) supplement with the FDA for its newly developed, long-lived, non-rechargeable sacral neuromodulation (SNM) implantable neurostimulator (INS).
  • Axonics expects to begin shipping the new non-rechargeable SNM system to customers upon FDA approval, which it anticipates receiving during the first half of 2022.
  • In addition, Axonics best-in-class urethral bulking agent, Bulkamid, provides women suffering from stress urinary incontinence (SUI) with safe and durable symptom relief.
  • Except as required by law, Axonics undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.

Axonics® Announces CE Mark Approval for Implantable Sacral Neurostimulator that Significantly Extends Recharge Interval

Retrieved on: 
Tuesday, May 18, 2021
Health, Medical Supplies, Medical devices, Branches of biology, Neurotechnology, Neuroscience, Sacral nerve stimulation, Neuromodulation, Overactive bladder, Percutaneous tibial nerve stimulation

This version reduces how frequently a patient needs to recharge their sacral neuromodulation device to just once a month for about one hour.

Key Points: 
  • This version reduces how frequently a patient needs to recharge their sacral neuromodulation device to just once a month for about one hour.
  • The company\xe2\x80\x99s rechargeable sacral neuromodulation (SNM) system provides patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy.
  • Axonics\xe2\x80\x99 clinically proven products are offered at hundreds of medical centers across the U.S. and abroad.
  • Reimbursement coverage is well established in the U.S. and is a covered service in most European countries.

Medtronic Receives FDA Approval to Launch Clinical Study for Implantable Tibial Neuromodulation Therapy for Bladder Incontinence

Retrieved on: 
Tuesday, April 27, 2021
Branches of biology, Neurotechnology, Medical specialties, Neuroscience, Urinary bladder disorders, Neuromodulation, Neurophysiology, Neuropsychology, Sacral nerve stimulation, Overactive bladder, Medtronic, Urology

Of those, 4.5 million are candidates for an advanced therapy, yet only 5% receive treatment3.

Key Points: 
  • Of those, 4.5 million are candidates for an advanced therapy, yet only 5% receive treatment3.
  • Implantable TNM aims to expand access to therapies for incontinence for more physicians and their patients.\nFor 25 years, Medtronic has pioneered sacral neuromodulation (SNM) therapy delivered by its implantable primary cell InterStim systems.
  • World Population Prospects: The 2010 Revision, CD-ROM Edition.\n3Leede Research, "Views on OAB: A Study for the National Association of Continence."
  • December 16, 2015.\n4Kobashi K, Nitti V, Margolis E et al.A prospective study to evaluate efficacy using the NURO percutaneous neuromodulation system in drug naive patients with overactive bladder syndrome.Urology.

Axonics® to Participate in the BofA Securities 2021 Virtual Healthcare Conference

Retrieved on: 
Thursday, April 22, 2021
Medical devices, Health, Branches of biology, Neurotechnology, Anatomy, Neuroscience, Sacral nerve stimulation, Neuromodulation, Overactive bladder, Urinary bladder, Incontinence

b'Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the BofA Securities 2021 Virtual Healthcare Conference on Thursday, May 13, 2021.\nAxonics is scheduled to present at 12:30 p.m. Eastern Time.

Key Points: 
  • b'Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the BofA Securities 2021 Virtual Healthcare Conference on Thursday, May 13, 2021.\nAxonics is scheduled to present at 12:30 p.m. Eastern Time.
  • The company\xe2\x80\x99s rechargeable sacral neuromodulation (SNM) system provides patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy.
  • Axonics\xe2\x80\x99 clinically proven products are offered at hundreds of medical centers across the U.S. and abroad.
  • Reimbursement coverage is well established in the U.S. and is a covered service in most European countries.

Axonics® to Report First Quarter 2021 Financial Results on May 6, 2021

Retrieved on: 
Thursday, April 15, 2021
Technology, Medical devices, Public relations, Investor relations, Communications, Software, Hardware, Health, General Health, Data management, Branches of biology, Neurotechnology, Anatomy, Neuroscience, Sacral nerve stimulation, Neuromodulation, Overactive bladder, Urinary bladder, Incontinence

b'Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, will report first quarter 2021 financial results after the market closes on Thursday, May 6, 2021.\nIn conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time.

Key Points: 
  • b'Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, will report first quarter 2021 financial results after the market closes on Thursday, May 6, 2021.\nIn conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time.
  • The company\xe2\x80\x99s rechargeable sacral neuromodulation (SNM) system provides patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy.
  • Axonics\xe2\x80\x99 clinically proven products are offered at hundreds of medical centers across the U.S. and abroad.
  • Reimbursement coverage is well established in the U.S. and is a covered service in most European countries.

Axonics® Expands into Stress Urinary Incontinence with the Acquisition of Bulkamid®

Retrieved on: 
Thursday, February 25, 2021
Biotechnology, Medical devices, Health, Pharmaceutical, Medical Supplies, Clinical medicine, Medical specialties, Medicine, Urinary incontinence, Stress incontinence, Incontinence, Urology, Sacral nerve stimulation

Interestingly, in many cases, the patient seeking treatment presents with mixed incontinence, meaning with both SUI and urge urinary incontinence symptoms.

Key Points: 
  • Interestingly, in many cases, the patient seeking treatment presents with mixed incontinence, meaning with both SUI and urge urinary incontinence symptoms.
  • The acquisition of Bulkamid is expected to be revenue growth, gross margin, and operating margin accretive to Axonics in 2021 and beyond.
  • Axonics has rights to a technology transfer after June 30, 2022 that would enable Axonics to insource the manufacturing of Bulkamid.
  • Based in Irvine, Calif, Axonics has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction, and through its acquisition of Bulkamid, offers solutions for patients with stress urinary incontinence.

Axonics® to Report Fourth Quarter and Fiscal Year 2020 Financial Results on February 25, 2021

Retrieved on: 
Monday, February 22, 2021
Health, Medical Supplies, Medical devices, Branches of biology, Neurotechnology, Neuroscience, Neuromodulation, Neurophysiology, Neuropsychology, Pain, Sacral nerve stimulation

Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will report fourth quarter and fiscal year 2020 financial results after the market closes on Thursday, February 25, 2021.

Key Points: 
  • Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will report fourth quarter and fiscal year 2020 financial results after the market closes on Thursday, February 25, 2021.
  • In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time.
  • Interested parties may access the live conference call by dialing 888-771-4371 (U.S.) or 847-585-4405 (International) and using passcode 50112306.
  • Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction.

Axonics® to Participate in the Society for Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2021 Winter Meeting

Retrieved on: 
Thursday, February 18, 2021
Health, Clinical trials, Medical devices, Branches of biology, Neurotechnology, Neuroscience, Neuromodulation, Sacral nerve stimulation

Axonics is sponsoring a symposium on Saturday, February 27, titled A New Era in Sacral Neuromodulation.

Key Points: 
  • Axonics is sponsoring a symposium on Saturday, February 27, titled A New Era in Sacral Neuromodulation.
  • The SUFU 2021 Winter Meeting provides an opportunity for physicians using the Axonics System to share their positive experience and strong clinical results with their peers, said John Woock, Ph.D., chief marketing officer of Axonics.
  • As a platinum sponsor of the conference, Axonics is providing numerous opportunities for physicians to learn more about the Axonics System.
  • Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction.

Axonics® Receives FDA Approval for Third-Generation Implantable Neurostimulator

Retrieved on: 
Tuesday, February 16, 2021
FDA, Health, Medical Supplies, Medical devices, Branches of biology, Neurotechnology, Neuroscience, Biology, Neuromodulation, Sacral nerve stimulation, Implant, Food and Drug Administration, Neurostimulation

Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has received PMA supplement approval from the U.S. Food & Drug Administration (FDA) for its third-generation implantable neurostimulator (INS).

Key Points: 
  • Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has received PMA supplement approval from the U.S. Food & Drug Administration (FDA) for its third-generation implantable neurostimulator (INS).
  • This marks the sixth FDA approval Axonics has received for a significant product innovation since the companys U.S. commercial launch in November 2019.
  • The FDA previously approved Axonics' second-generation rechargeable INS in April 2020, which extended the recharge interval to one hour each month.
  • Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction.